Lebrikizumab shows promise in adolescents with uncontrolled asthma

SAN FRANCISCO — Lebrikizumab reduced exacerbations in adolescents with uncontrolled asthma and had a favorable safety profile, according to results of the ACOUSTICS study.
The study, which was stopped early by the sponsor, showed a greater treatment effect with the higher dose of lebrikizumab studied.
Stanley J. Szefler, MD, researcher in the department of pediatrics at the Children’s Hospital Colorado and University of Colorado School of Medicine, reported results from the phase 3, multicenter, randomized, double-blind, placebo-controlled ACOUSTICS study at the American Thoracic

SAN FRANCISCO — Lebrikizumab reduced exacerbations in adolescents with uncontrolled asthma and had a favorable safety profile, according to results of the ACOUSTICS study.
The study, which was stopped early by the sponsor, showed a greater treatment effect with the higher dose of lebrikizumab studied.
Stanley J. Szefler, MD, researcher in the department of pediatrics at the Children’s Hospital Colorado and University of Colorado School of Medicine, reported results from the phase 3, multicenter, randomized, double-blind, placebo-controlled ACOUSTICS study at the American Thoracic